Dickinson Andrew D sold $415K of GILD
Dickinson Andrew D (Chief Financial Officer) sold 3,000 shares of GILEAD SCIENCES, INC. (GILD) at $138.36 ($0.42M total) on 2026-08-17 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
For trading, the key takeaway is that the transaction is pre-arranged, which generally dampens the informational content. It may still marginally affect short-term sentiment among retail and systematic flows that screen insider activity.
Market read
A CFO insider sale was disclosed, but the 10b5-1 structure suggests limited incremental fundamental information.
What to watch
The article provides only the sale details, not any offsetting buys, and does not indicate whether the executive’s broader trading window or planned schedule implies future selling.
Background
The article is a primary-source SEC Form 4 insider transaction for Gilead Sciences, filed 2026-08-18, showing a CFO open-market sale under a 10b5-1 plan.
Ticker impact
Gilead CFO Andrew D. Dickinson sold 3,000 shares in an open-market transaction at $138.36 on 2026-08-17 under a 10b5-1 plan.
Low likelihood of a sustained price move driven solely by this Form 4 sale.
The filing specifies an open-market sale and confirms a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.
Market effects
No clear sector read-through; this is company-specific insider transaction disclosure.
None.
None.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still coincide with internal views on valuation or liquidity needs, so some traders may treat it as a mild negative sentiment input.
Key entities
- issuerGilead Sciences, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderAndrew D. Dickinson
Chief Financial Officer who sold shares.
- trading mechanism10b5-1 plan
Pre-arranged plan that typically reduces discretionary signaling.
